Agios Pharmaceuticals Inc Has Another Very Negative Options Trading Session

 Agios Pharmaceuticals Inc Has Another Very Negative Options Trading Session

In today’s session Agios Pharmaceuticals Inc (AGIO) recorded an unusually high (263) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious AGIO decrease. With 263 contracts traded and 1514 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: AGIO161118P00050000 closed last at: $1.2 or 40% down. About 376,645 shares traded hands. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 25.53% since April 8, 2016 and is uptrending. It has outperformed by 19.88% the S&P500.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Ratings Coverage

Out of 12 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 7 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 58% are positive. Agios Pharmaceuticals has been the topic of 20 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Needham initiated Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Monday, October 24 with “Buy” rating. The firm has “Hold” rating by Canaccord Genuity given on Friday, August 7. The firm earned “Market Perform” rating on Monday, December 7 by Leerink Swann. The firm has “Outperform” rating given on Wednesday, May 18 by Credit Suisse. Northland Capital initiated it with “Outperform” rating and $132 target price in Thursday, July 23 report. On Monday, June 13 the stock rating was upgraded by JP Morgan to “Overweight”. The stock has “Neutral” rating given by Janney Capital on Wednesday, March 2. The rating was upgraded by Canaccord Genuity to “Buy” on Monday, June 13. Roth Capital maintained Agios Pharmaceuticals Inc (NASDAQ:AGIO) rating on Wednesday, August 5. Roth Capital has “Hold” rating and $114 price target. The stock has “Outperform” rating given by Credit Suisse on Thursday, January 21.

According to Zacks Investment Research, “Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It discovers and develops therapeutics in the field of cancer metabolism and inborn errors of metabolism. The Company’s products include AG-221, AG-120, enzyme glutaminase and AG-348. Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment increased to 1.39 in 2016 Q2. Its up 0.03, from 1.36 in 2016Q1. The ratio is positive, as 22 funds sold all Agios Pharmaceuticals Inc shares owned while 37 reduced positions. 18 funds bought stakes while 64 increased positions. They now own 35.06 million shares or 11.59% more from 31.42 million shares in 2016Q1.
Jacobs Levy Equity Mgmt Inc holds 33,190 shares or 0.03% of its portfolio. Cormorant Asset Mngmt Ltd Liability Co accumulated 50,000 shares or 0.3% of the stock. Baker Bros Advsrs Lp holds 0.09% or 207,915 shares in its portfolio. New York State Common Retirement Fund holds 0.01% or 93,435 shares in its portfolio. Bb Biotech Ag, a Switzerland-based fund reported 2.36 million shares. Cornerstone Advsr Inc holds 0.01% or 122 shares in its portfolio. The California-based California Employees Retirement has invested 0% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Sectoral Asset Inc has invested 0.16% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Moreover, Jpmorgan Chase And has 0% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 30,882 shares. Td Asset Mngmt has 13,200 shares for 0% of their US portfolio. Invsts owns 1.50M shares or 0.09% of their US portfolio. Invesco Ltd last reported 0% of its portfolio in the stock. Ladenburg Thalmann Financial Svcs has 0% invested in the company for 127 shares. Paradigm Asset accumulated 9,100 shares or 0% of the stock. Deutsche Bank & Trust Ag owns 238,135 shares or 0.01% of their US portfolio.

Insider Transactions: Since May 25, 2016, the stock had 0 insider purchases, and 8 selling transactions for $2.90 million net activity. 27,500 Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares with value of $1.79M were sold by Biller Scott. $93,424 worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) was sold by Cantley Lewis Clayton Jr..

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $2.84 billion. The Firm is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders , which are a subset of orphan genetic metabolic diseases. It currently has negative earnings. The Company’s cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

AGIO Company Profile

Agios Pharmaceuticals, Inc., incorporated on August 7, 2007, is a biopharmaceutical company. The Firm is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. The Company’s cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its RGD programs, AG-348, which targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency.

More important recent Agios Pharmaceuticals Inc (NASDAQ:AGIO) news were published by: Fool.com which released: “Why Agios Pharmaceuticals Inc Stock Skyrocketed Today” on September 07, 2016, also Fool.com published article titled: “Why Agios Pharmaceuticals Inc. Presented Lower Today”, Fool.com published: “3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016” on July 03, 2016. More interesting news about Agios Pharmaceuticals Inc (NASDAQ:AGIO) was released by: Fool.com and their article: “A Short Squeeze and the Rumor Mill Stir Up Agios Pharmaceuticals, Inc. in April” with publication date: May 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment